Post-Trial Access TAK-609

Apr 4, 2023 | Clinical Trials, News

Takeda has announced a Post-Trial Access program for patients currently enrolled in extension trials for TAK-609, a treatment for MPS II Hunter syndrome. This program will provide continued access for patients who have benefited from treatment on existing studies. This is not a new recruiting clinical trial.  This information has now been updated on the National Institutes of Health website, The website lists this as “Post-Trial Access Program Idursulfase-IT (HGT-2310) in Conjunction with Intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cognitive Impairment.”

View the announcement >>